Latest News

Geared toward facilitating earlier detection and efficiencies in emergency department workflow, the AI triage software reportedly has 11 newly cleared indications.

In a prospective comparison with prior criteria for evaluating hepatocellular carcinoma surveillance, the American Association for the Study of Liver Diseases (AASLD) version 2023 system offered significantly higher sensitivity.

In a recent interview, Manisha Bahl, M.D., discussed recent research demonstrating a significant decline in the sensitivity of digital breast tomosynthesis (DBT) with increasing breast density as well as challenges in the utilization of supplemental imaging for women with dense breasts.

In a seven study meta-analysis with a total of 493 cases involving high-risk breast lesions, researchers found that contrast-enhanced breast MRI did not miss any cases of invasive breast cancer.

In a recent interview, David Yankelevitz, M.D., discussed the recent FDA clearance of the AI-CVD multisystem screening software and the ongoing evolution of incorporating computed tomography into personalized screening and risk assessments.

Incorporating AI to reduce artifacts and bolster soft tissue contrast, the Elekta Evo CT-Linac system reportedly improves detection of tumors and organs-at-risk.

While some job offers may sound very tempting, savvy radiologists ask prospective employers to show more than the money in order to assess a potential jump for a new gig.

Catch up on a variety of new FDA clearances in radiology from the past week.

Catch up on the top radiology content of the past week.

From satisfaction of search to grouped microcalcifications and challenges with isodense asymmetries and blind spots, the authors of a new review discuss contributing factors and preventive measures to avoid missed diagnoses of breast cancer in mammography interpretation.

In a recent interview, Rajesh Bhayana, M.D., discussed pertinent findings from a new study examining the use of the large language model GPT-4o in facilitating protocoling for abdominal and pelvic CT exams.

Offering a biocompatible, non-metallic alternative to metallic tumor markers, the VM1 tumor marker reportedly offers artifact-free visibility across a variety of breast imaging including mammography, ultrasound and MRI.

In what may be the largest study to assess digital breast tomosynthesis (DBT) screening of women with dense breasts, researchers noted only a 61.8 percent sensitivity for women with extremely dense breasts.